News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Phase 3 data expected in the second half of 2024
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Arrow is the marketing partner in US
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Subscribe To Our Newsletter & Stay Updated
